Lesofavumab is a recombinant monoclonal antibody to Influenza B virus hemagglutinin. Lesofavumab is a human monoclonal antibody that can be potentially used in the treatment of Influenza B infection. Genentech, a subsidiary of Roche, is developing Lesofavumab (RG6024), a monoclonal antibody, for the treatment of influenza B infections.
Research Grade Lesofavumab
Overview
Catalog No.
VK515056
Host species
Human
Species reactivity
Influenza B virus
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Purity
>95% purity as determined by SDS-PAGE.
Clonality
Monoclonal
Isotype
IgG1, kappa
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Target
HA/Hemagglutinin
Purification
Protein A/G purified from cell culture supernatant.
Endotoxin level
Please contact the lab for this information.
Expression system
Mammalian Cells
Accession
P03461
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternative name
RG6024, RG6024, MHAB5553A, RG70026, RO7045557, 1807960-57-1
Note
For research use only. Not suitable for clinical or therapeutic use.
Description
Images
Bioactivity
SEC-HPLC detection for Research Grade Lesofavumab.
SDS-PAGE
SDS-PAGE for Research Grade Lesofavumab.